70 related articles for article (PubMed ID: 11701723)
1. Fetal antigen 1 in healthy adults and patients with pituitary disease: relation to physiological, pathological, and pharmacological GH levels.
Andersen M; Jensen CH; Støving RK; Larsen JB; Schrøder HD; Teisner B; Hagen C
J Clin Endocrinol Metab; 2001 Nov; 86(11):5465-70. PubMed ID: 11701723
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
4. Expression, biosynthesis and release of preadipocyte factor-1/ delta-like protein/fetal antigen-1 in pancreatic beta-cells: possible physiological implications.
Friedrichsen BN; Carlsson C; Møldrup A; Michelsen B; Jensen CH; Teisner B; Nielsen JH
J Endocrinol; 2003 Feb; 176(2):257-66. PubMed ID: 12553874
[TBL] [Abstract][Full Text] [Related]
5. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
[TBL] [Abstract][Full Text] [Related]
6. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
Losa M; Schopohl J; König A; Müller OA; von Werder K
J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
[TBL] [Abstract][Full Text] [Related]
8. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
Gelato MC; Oldfield E; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
[TBL] [Abstract][Full Text] [Related]
9. Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults.
Hoeck HC; Jakobsen PE; Vestergaard P; Falhof J; Laurberg P
Growth Horm IGF Res; 1999 Feb; 9(1):18-24. PubMed ID: 10207504
[TBL] [Abstract][Full Text] [Related]
10. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
[TBL] [Abstract][Full Text] [Related]
11. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
13. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH.
Tsushima T; Katoh Y; Miyachi Y; Chihara K; Teramoto A; Irie M; Hashimoto Y
J Clin Endocrinol Metab; 1999 Jan; 84(1):317-22. PubMed ID: 9920101
[TBL] [Abstract][Full Text] [Related]
15. Deterioration of growth hormone (GH) response and anterior pituitary function in young adults with childhood-onset GH deficiency and ectopic posterior pituitary: a two-year prospective follow-up study.
di Iorgi N; Secco A; Napoli F; Tinelli C; Calcagno A; Fratangeli N; Ambrosini L; Rossi A; Lorini R; Maghnie M
J Clin Endocrinol Metab; 2007 Oct; 92(10):3875-84. PubMed ID: 17666476
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.
Ghigo E; Mazza E; Imperiale E; Rizzi G; Benso L; Müller EE; Camanni F; Massara F
J Clin Endocrinol Metab; 1987 Sep; 65(3):452-6. PubMed ID: 3114300
[TBL] [Abstract][Full Text] [Related]
17. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus.
Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F
Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028
[TBL] [Abstract][Full Text] [Related]
19. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly.
Biermasz NR; Pereira AM; Frölich M; Romijn JA; Veldhuis JD; Roelfsema F
Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E25-30. PubMed ID: 14506078
[TBL] [Abstract][Full Text] [Related]
20. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
